Survival-free from progression to AP or BP. At 36 months the actuarial proportion of patients alive and progression-free was 88% (95% CI, 84%-92%) in the high-dose arm (HDA) and 86% (95% CI, 82%-90%) in the standard-dose arm (SDA). P = .63 log-rank test. No patient was censored before last contact, death, or progression. Total number of progressions was 9 in the HDA and 11 in the SDA.